Targeted protein degradation for cancer therapy

Area of Science:

• Biochemistry
• Molecular Biology
• Drug Discovery

Background:

• Targeted protein degradation (TPD) leverages the ubiquitin-proteasome system for selective protein elimination.
• Significant advancements in proteolysis targeting chimeras (PROTACs) and molecular glue degraders have spurred therapeutic interest.

Purpose of the Study:

• To review recent progress in targeted protein degradation (TPD).
• To highlight novel degrader modalities, clinical candidates for cancer therapy, and future design strategies.

Main Methods:

• Review of recent scientific literature and clinical trial data.
• Analysis of structural and mechanistic insights into protein degrader design.

Main Results:

• PROTACs are nearing clinical approval, with ongoing research into rational design.
• Discovery of novel TPD modalities beyond PROTACs and molecular glues.
• Emerging clinical applications of protein degraders in cancer therapy.

Conclusions:

• The field of TPD is rapidly expanding with diverse modalities and therapeutic potential.
• Continued innovation in design approaches promises to unlock new therapeutic avenues for various diseases.